权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Exosomal RNA: A Novel Signature Guide for Prostate Cancer Proton Therapy

外泌体 RNA：前列腺癌质子治疗的新特征指南

基本信息

批准号：
10302817
负责人：
Simone Olivia Heyliger
金额：
$ 2.88万
依托单位：
HAMPTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10302817
关键词：
Achievement African American Area Biological Markers Biopsy Blood Blood specimen Body Fluids Cancer Patient Cells Cerebrospinal Fluid Cessation of life Clinical Collaborations DNA Data Decision Making Detection Development Disease European Evaluation Excision Feasibility Studies Future Genes Genetic Genomics Goals Grant Health Historically Black Colleges and Universities Human Institutes Joints Legal patent Lipids Liquid substance Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Measurement Measures Messenger RNA Modality Molecular Monitor Neoplasm Metastasis Newly Diagnosed Normal Cell Operative Surgical Procedures Outcome Outcomes Research Patients Physicians Preparation Process Prostate Prostate-Specific Antigen Prostatectomy Prostatic RNA Radiation Monitoring Radiation therapy Radical Prostatectomy Recurrence Research Research Infrastructure Rest Risk Risk Assessment Saliva Sampling Site Testing Time Study Tissues Toxic effect Universities Urine Urologic Oncology Urology Vesicle Virginia Work anticancer research base cancer genomics clinical decision-making cohort detection method exosome extracellular vesicles follow-up improved liquid biopsy medical schools men microvesicles neoplastic cell non-invasive monitor novel particle prognostic prostate biopsy protein metabolite proton therapy recruit response response biomarker serum PSA specific biomarkers tool trafficking treatment response tumor tumor microenvironment unnecessary treatment

项目摘要

Project Summary / Abstract Proton therapy (PT) is a form of radiation therapy used to treat prostate cancer patients that can be an alternative to surgery. While PT is thought to risk less toxicity than conventional radiation therapy, much about PT is still not understood. To help serve their local area of tidewater Virginia, which has one of the highest rates of prostate cancer in the world, especially in African-Americans, Hampton University (HU), a Historically Black University, has opened the Hampton University Proton Therapy Institute. To help build the research capacity at HU, leveraging their clinical expertise in proton therapy, the Icahn School of Medicine at Mount Sinai (ISMMS) and HU propose this joint project aimed at developing a noninvasive biomarker for response to PT. The team at ISMMS will bring their expertise in genomics and exosome profiling, a noninvasive way to measure particles that are thought to shed from the tumor, to this project and in the process help build the research capacity at HU. The research goal of this project is to determine changes in the exosomal RNA (exoRNA) profile of exosomes taken from prostate cancer patients before and after radiotherapy with PT. All aims of the study use patient samples collected at the HUPTI by the HU team. In aim 1, we will ask if an exosomal signature of radical prostatectomy shows similar changes before and after PT. In aim 2, to determine if there are specific changes in the mRNA profile in response to PT, we will globally profile RNA isolated from exosomes before and after PT. In aim 3, to continue to build this project in preparation for a future collaborative R01 submission, we will recruit additional patients from HUPTI to this study and obtain blood specimens before, during, and after PT. At the end of the study time period, our scientific achievement will have been to determine what changes in the RNA profile of exosomes can be observed in response to PT. This will be important preliminary data demonstrating the utility of exosomes for noninvasive monitoring of PT. More importantly, through this collaborative partnership between ISMMS and HU, we will have enhanced the research infrastructure of HU in a way that will allow HU to pursue further research both jointly with ISMMS and independently building on their clinical expertise in proton therapy.

项目摘要/摘要